Parexel Expands Global Reach with New Hub in India

Friday, June 22, 2007

Waltham, Mass.-based contract research organization (CRO) Parexel International has opened a major clinical operations and data management office in Hyderabad, India. The office will serve as the company’s main hub in the region and will expand its presence in the emerging Indian clinical trials market. Although Parexel already operates an 86-bed phase I unit in Ahmedabad, through a joint venture with the CRO Synchron, this would be the company’s first late phase clinical operations office in the region.

[Read More]

BBK Creates New Global Mobilization Team Division

Tuesday, June 19, 2007

Newton, Mass.-based patient recruitment company BBK Worldwide has created a new company division called the global mobilization team. The company stated that this division will help address the challenges of planning and deploying of resources for large-scale, global trials. BBK stated the division will include in-country staff with expertise in local patient recruitment, a web-based communication structure and real-time access to data essential for making changes in recruitment operations mid-trial.

[Read More]

Wellquest Opens New Research Facility in Hyderabad

Monday, June 18, 2007

Mumbai-based Wellquest CRO, the clinical outsourcing division of India pharmaceutical company Nicholas Piramal, opened a 30,000 square foot research facility in Hyderabad. The 112-bed center boasts separate wards for female and pediatric subjects. The unit will be Wellquest’s second facility in India, which runs a 20,000 square foot center at the Wellspring Hospital in Mumbai. The Mumbai facility consists of a 60-bed ward, six-bed ICU, pharmacy, phlebotomy stations, bioanalytical laboratory and an accredited central pathology laboratory. Wellquest was established in 2000 by Nicholas Piramal and has conducted about 100 pivotal trials and 40 pilot studies. Both facilities are complaint with Good Clinical Practice and Good Laboratory Practice guidelines.

[Read More]

Sanofi Aventis and Taiho Report Positive Results In Stomach Cancer Drug

Thursday, June 14, 2007

Sanofi Aventis and Taiho Pharmaceutical reported positive results from a phase III trial of S-1 for the treatment of gastric cancer, at the 43rd Annual Meeting of the American Society of Clinical Oncology. This randomized trial, dubbed SPIRTS, enrolled 305 subjects in Japan. Subjects were randomized to receive either oral S-1 (40 mg/m2) twice daily for 28 days followed by a 14-day rest period, or oral S-1(40 mg/m2) twice daily for 21 days plus IV cisplatin on the eighth day of treatment, followed by the 14-day rest period.

[Read More]

Private Equity Group Acquires Radiant Research to Grow the SMO Globally

Monday, June 11, 2007

Bellevue, Wash.-based Radiant Research, the largest owned-model site management organization (SMO) with 26 sites, has completed a sale of the business to an ownership group led by ICICI Venture, a private equity company with $2 billion under management. Company officials said June 8th that Radiant will continue to provide development, study conduct and centralized patient recruitment services.

[Read More]